{"id":"46cc3b60f2b2","type":"article","url":"https://hartvaat.nl/2026/03/09/semaglutide-stimuleert-anti-inflammatoire-stamcelflux-vanuit-beenmerg/","title":"Semaglutide stimuleert anti-inflammatoire stamcelflux vanuit beenmerg","title_en":"Semaglutide promotes bone marrow-derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["cagrisema","canagliflozine","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","orforglipron","select-trial","semaglutide","tirzepatide"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf690","source_url":"https://doi.org/10.1093/eurheartj/ehaf690","authors":["Brady Park","Fallon Dennis","Arianna Z He","Aishwarya Krishnaraj","Ehab Bakbak","Cole J Dennis","Yi Pan","Elizabeth Misner","Veena Thayanithy","Bhavaani Lambotharan","Vaasudevan Lambotharan","Aruna Lambotharan","C David Mazer","Adrian Quan","Hwee Teoh","David A Hess","Subodh Verma"],"significance":6,"published":"2026-03-09","source_date":"2026-03-09","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"This translational study showed that semaglutide mobilizes anti-inflammatory and pro-regenerative progenitor cells from the bone marrow, providing a novel mechanistic explanation for the cardiovascular benefit of GLP-1 receptor agonists.","created":"2026-07-03T10:32:13Z","updated":"2026-07-03T13:31:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Translationele studie toonde dat semaglutide anti-inflammatoire progenitorcellen mobiliseert vanuit het beenmerg. Dit mechanisme draagt bij aan de vasculaire bescherming door GLP-1-agonisten.","abstract_original":"BACKGROUND AND AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major atherosclerotic cardiovascular events in individuals living with either diabetes or obesity. Since the turnover of vascular regenerative (VR) stem and progenitor cells has been demonstrated to modulate vessel repair and atherothrombotic risk, this study aimed to determine the effect of the GLP-1RA semaglutide on the levels of circulating VR cells. METHODS: SEMA-VR CardioLink-15 was a randomized translational trial of usual care vs semaglutide for 6 months in 46 participants with either type 2 diabetes and/or obesity plus atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk factors. Vascular regenerative cells were enumerated using multi-parametric flow cytometry for high aldehyde dehydrogenase activity (ALDHhi) and lineage-specific cell surface marker expression. The primary endpoint was the 6-month change in VR cell content. RESULTS: Compared with usual care (n = 24), semaglutide (n = 22) led to a greater increase in the number of VR cells [high aldehyde dehydrogenase 1A1 activity and low side scatter (ALDHhiSSClow): +0.8% vs +34.8%; P = .036], pan-haematopoietic myeloid progenitors (ALDHhiSSClowCD45+: +2.8% vs +40.1%; P = .017), and endothelial precursors (ALDHhiSSClowCD34+ CD133+ CD45-: -2.3% vs +66.2%; P = .037) from baseline. Semaglutide also decreased granulocyte precursors (ALDHhiSSChi: +0.3% vs -50.8%; P = .002), particularly those expressing the neutrophil activation marker CD66b and chemokine receptor CXCR2. Semaglutide down-regulated serum proteins over-represented in pro-inflammatory tumour necrosis factor and interleukin signalling pathways. CONCLUSIONS: In people living with either type 2 diabetes or obesity plus ASCVD risk, semaglutide increased circulating VR cell content while reducing pro-inflammatory granulocyte precursors and cytokine production. Collectively, these findings suggest that semaglutide may improve endogenous progenitor cell-mediated blood vessel repair processes."}